Every intervention Outliyr has scored for heart health, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for heart health; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
74 of 136 evaluated interventions score 3.0+ out of 10 for heart health · 28 comparisons
Guan 2020 reports Confirmed meta-analysis on obesity, BP, and lipid outcomes; supports cardiometabolic breadth. Tzang 2024 points in the same direction, but route, dose, baseline status, and outcome tracking decide whether Taurine…
The Norwegian 4x4 protocol combines four minutes of near-maximal effort with three minutes of active recovery, a pattern that consistently outperforms moderate continuous training in heart-failure and post-infarction cohorts. While the multicenter…
Lang 2024 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: Cardiorespiratory fitness is one of the strongest health predictors in the literature. this verified…
In the KIHD cohort, Laukkanen 2015 found 4 to 7 weekly sessions associated with a fatal cardiovascular disease hazard ratio of 0.50 and a sudden cardiac death hazard ratio of 0.37 versus…
Hamaya 2025 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: Waon therapy clinical data support cardiovascular benefit when supervised: this verified source reported improved…
Slow-breathing meta-analyses support clinically meaningful systolic blood-pressure reduction in nonclinical populations per the broader 2024 Shao Mindfulness review of slow-breathing interventions; baroreflex sensitivity improves measurably with practice. The score stays bounded because…
Argeros 2025 anchors the most relevant signal. Magnesium fits cardiovascular when low intake, stress load, mineral loss, or a form-specific target makes deficiency correction plausible. The score stays bounded because effects are…
Lincoff 2023 reported 20% lower 3-point MACE in adults with overweight or obesity and established CVD without diabetes. That makes Semaglutide more than a weight-loss drug for high-risk patients. The effect likely…
Sesso 2022, the COSMOS RCT in 21,442 older adults, found a cocoa-flavanol supplement (500 mg/day) cut cardiovascular death 27 percent (HR 0.73) over a median 3.6 years, though the primary composite missed…
Kiechl 2018 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: this verified source supports cardiac autophagy and diastolic-function mechanisms in animals; this verified source…
Tirzepatide shows promise for heart-failure with preserved ejection fraction in obese patients, where a trial demonstrated reduced composite clinical events and better health status versus placebo. The evidence tier remains moderate because…
The blood-pressure signal is real and replicated. Machowiec 2021 pooled 5 randomized trials in 230 subjects and found systolic pressure falling 4.59 mmHg and diastolic falling 7.02 mmHg, with the largest effect…
The evidence reaches hard outcomes, not just biomarkers. In chronic heart failure, Mortensen 2014 (Q-SYMBIO, n=420) found 300 mg/day cut major adverse cardiac events from 26% to 15% (hazard ratio 0.50) and…
Jamialahmadi 2024 reports 7 trials; reported reductions in total cholesterol, triglycerides, and LDL, with no significant HDL change. Ye 2026 points in the same direction, but route, dose, baseline status, and outcome…
UKPDS reported lower myocardial infarction and all-cause mortality in overweight patients with newly diagnosed type 2 diabetes UK Prospective Diabetes Study Group 1998. A 10-year post-trial follow-up found that the Metformin subgroup…
Rucking is built on walking, the movement with the strongest population mortality data. A 15-cohort meta-analysis of 47,471 adults found the highest step quartile had a hazard ratio of 0.47 for all-cause…
Weston 2014 found interval training raised VO2peak about 3 mL/kg/min more than moderate continuous training in cardiometabolic-disease patients, roughly double the improvement. Under medical supervision, even high-intensity work is well tolerated in…
LDL-C, triglycerides, and total cholesterol improve in dyslipidemic adults in Koppen 2017 and Blais 2023. The PCSK9, NPC1L1, and bile-acid mechanisms make cardiovascular use more credible than generic wellness use, but berberine…
Systemic reviews such as Miller 2021 describe vascular and cardiovascular effects, but the hemodynamic response requires population-specific caution. The score stays bounded because Blood-Flow Restriction Training evidence for cardiovascular can depend on…
Laurindo 2025 reports 8 randomized controlled studies; 312 randomized participants by included-study table; triglycerides and HDL-C improved; LDL-C and total cholesterol were not significant; certainty low to very low. American points in…
Vasireddi 2025 anchors the most relevant signal. BPC-157 fits cardiovascular when the target is tissue repair, vascular recruitment, or inflammation control, but the case still rests mostly on preclinical models. The score…
Cardiac repair evidence is mostly preclinical. Bock-Marquette 2004 showed improved cardiac function after coronary ligation in mice, while Zhou 2011 found TB4 did not reprogram epicardial cells into cardiomyocytes after myocardial infarction.…
Harrison 2009 anchors the most relevant signal. Rapamycin fits cardiovascular when mTORC1 modulation, autophagy, immune aging, or senescence biology is the actual target. The score stays bounded because human longevity endpoints remain…
The observational signal is unusually consistent. Smith 2020 followed 3,236 adults for a median 21.4 years and found each 1 SD higher plasma ergothioneine tracked with a coronary-disease hazard ratio of 0.85…
Fallah 2018 pooled 19 RCTs (n=797) and found total cholesterol down 9.09 mg/dL, LDL down 8.32 mg/dL, and systolic blood pressure down 4.51 mmHg, all statistically significant. The effect sizes are modest,…
Senescent endothelial-cell clearance supports vascular function in preclinical models; human cardiovascular outcome data for F+Q is absent. The score stays bounded because Senolytics evidence for cardiovascular can depend on age, disease context,…
Resveratrol's most credible signal is cardiovascular-risk support rather than broad prevention. Tomé-Carneiro 2012 reported inflammatory and fibrinolytic improvements with a grape nutraceutical in primary CVD prevention, but this corpus has product and…
Borra 2025 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: Potassium intake improves blood pressure and cardiovascular risk factors per this verified source; magnesium…
Knapen 2015 anchors the most relevant signal. Vitamin D3 + K2 fits cardiovascular when deficiency, bone risk, immune seasonality, or fat-soluble nutrient gaps are present. The score stays bounded because benefits are…
The Juraschek 2012 meta-analysis of 29 randomized trials (median dose 500 mg/day, median 8 weeks) found a pooled systolic reduction of 3.84 mmHg, rising to 4.85 mmHg in hypertensive participants, with a…
The evidence points to a plausible use case without proving a universal response. Abuknesha et al. 2025 is the best anchor here because it reports 34 randomized trials, 114,326 participants and atrial…
Tesamorelin improves some cardiometabolic risk surrogates through VAT reduction, triglyceride changes, inflammatory-marker shifts, and possibly carotid or adipose-quality pathways. Stanley 2011 supports inflammatory-marker improvement tied to VAT response. The score stays bounded…
The most interesting therapeutic-adjacent signal. Nielsen 2019 gave acute 3-hydroxybutyrate to 16 chronic heart-failure patients and saw cardiac output rise about 2.0 L per minute with an 8-point bump in ejection fraction,…
Rosenstock 2023 makes the claim plausible but incomplete. The existing rationale points to this narrower claim: Weight, blood pressure, triglyceride, glucose, and inflammation markers likely move favorably, but no completed cardiovascular outcomes…
Soh 2024 anchors the most relevant signal. Glycine fits cardiovascular because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the endpoint. The score stays bounded because many…
Liu D et al. 2022 is the best anchor here because it reports 139 participants adults with obesity and TRE plus calorie restriction did not add significant weight-loss or cardiometabolic advantage over…
Quercetin lowers systolic BP by about 3.04 mmHg and diastolic BP by about 2.63 mmHg in the Serban 2016 meta-analysis of 7 RCTs (n=587), with effects strongest at doses 500 mg/day or…
Solerte 2008 reports Personally verified PMID; sarcopenia crossover study reporting lean-mass gains with amino acid supplementation. The score stays conditional because Essential Amino Acids still needs better outcome data for this exact…
A 2024 meta-analysis notes that Whole-Body Vibration produces acute heart-rate and blood-pressure spikes comparable to light-intensity exercise Wang 2024. While short-term hemodynamic responses suggest a mild aerobic stimulus, no randomized trials have…
The single isolated-fucoidan human RCT, Hernandez-Corona 2014, gave 500 mg per day to 25 overweight adults for three months and found lower diastolic blood pressure and lower LDL-C. That is a genuine…
The evidence points to a plausible use case without proving a universal response. Zhao C et al. 2026 is the best anchor here because it reports approval-focused review: Barth syndrome rationale, crossover…
The nearest human signal is a deep-sea-water proxy, not the branded product. Ham 2020 ran a double-blind crossover RCT in 37 prediabetic adults using magnesium-rich deep-sea water (350 mg magnesium daily, 8…
The study showed that SLU-PP-332 enhanced ejection fraction, reduced fibrosis, and improved survival markers in a rodent model of pressure overload. Separate work by Billon 2023 demonstrated that SLU-PP-332 boosts aerobic exercise…
Filip 2007 gives the most relevant evidence anchor. The existing rationale points to this narrower claim: Mechanism is mostly neutral, while calcium load creates a dose-dependent caution. this verified source is calcium-supplement…
Earthing's cardiovascular use case rests on a handful of small, unblinded or narrative studies that suggest modest effects on heart-rate variability and blood viscosity, but none meet the criteria for high-quality randomized…
Conze 2019 is the cleanest verified anchor for this report. The existing rationale points to this narrower claim: this verified source found directional blood-pressure and arterial-stiffness signals in middle-aged and older adults…
Cardiovascular evidence is reassuring but not yet a finished story. In its largest safety study the drug was noninferior to insulin glargine for major cardiovascular events, with a hazard ratio of 0.84,…
Lincoff 2023 reports TRAVERSE cardiovascular outcomes trial in 5,246 hypogonadal men with cardiovascular risk; major cardiovascular events non-inferior, with monitoring-relevant safety signals. Cruickshank 2024 points in the same direction, but route, dose,…
Cardiovascular evidence is observational and indirect rather than RCT-anchored. Higher cruciferous vegetable intake is associated with lower stroke and cardiovascular mortality in cohort work (Joshipura 1999, Zhang 2011), and air pollution detox…
HBOT has vascular and angiogenic mechanisms with small evidence in peripheral ischemia and erectile function. It is not a general cardiovascular prevention tool. Hadanny 2018 supports vascular endothelial effects in selected patients…
Cardiovascular benefit is inferred from the inflammation and glycemic effects rather than from hard endpoint data. There are no large trials showing curcumin reduces heart attacks or strokes. The lipid data is…
The cardiovascular score is unchanged because fibrinogen, antioxidant, and fibrosis pathways are relevant but indirect. Pickart 2014 discusses fibrinogen and tissue-repair genes, but no human cardiovascular endpoint trial supports risk reduction.
Cardiac repair has strong preclinical and mechanistic groundwork through the Bock-Marquette and Smart series showing Tβ4 activates integrin-linked kinase and mobilizes epicardial progenitors, per Bock-Marquette 2004, but the only RGN-352 Phase 2…
Kumar 2023 reported lower systolic blood pressure and improved endothelial function in older adults, and the pilot noted reduced endothelial dysfunction, but these are small trials without cardiovascular event endpoints, so the…
Cardiovascular benefit is plausible but unproven for CagriSema specifically. Weight loss of this magnitude usually improves blood pressure and lipids, and the GLP-1 class has positive cardiovascular outcomes data from related drugs.…
Preserved v0.x score. Cardiovascular prevention is a poor benefit-risk fit because systemic blood routes create the most important cardiovascular safety issue: gas embolism and paradoxical embolism risk. Marchetti and La Monaca 2000…
Acute blood-pressure reduction under stress is plausible from stress-challenge work, but this is not a standalone cardiovascular intervention.
Cardiovascular relevance is mostly secondary to sepsis and critical illness outcomes. Wu 2013 tracked severe sepsis outcomes, but no primary cardiovascular prevention or treatment indication is established.
Zhang 2025 supports modest blood-pressure and lipid-marker improvements in metabolic syndrome-related populations, but there are no hard cardiovascular outcome trials.
Cardiovascular response is mixed: triglycerides and HDL often improve, while LDL-C and ApoB can rise meaningfully in responders. Buren 2021 found LDL-C increased in healthy young normal-weight women after ketogenic LCHF feeding,…
Preclinical vascular data from de Picciotto 2016 support vascular-aging mechanisms, and Zhang 2026 found a small diastolic blood-pressure signal. No cardiovascular-event RCT exists.
Reishi metabolic-syndrome RCT (Klupp 2016) found no blood pressure or lipid benefit; cordyceps cardiovascular data are preclinical. Mechanistic plausibility without human outcomes.
Acute sessions increase cardiovascular work, and improved muscle mass may support vascular health. The evidence is not strong enough to position WB-EMS as a cardiovascular treatment or replacement for aerobic training.
Cardiovascular benefit is indirect and modest. Stress, cortisol, sleep, inflammation, and blood-pressure endpoints can move in favorable directions in some trials, including Salve 2019. Ashwagandha is not a primary cardiovascular therapy, and…
Short-term standardized-extract trials generally do not show major liver, kidney, or lipid shifts, but there is no cardiovascular endpoint evidence. Estradiol can rise through aromatization in susceptible men.
No proven cardiovascular benefit yet, and a heart-rate flag. A blood-pressure post-hoc was favorable, but a dedicated outcomes trial has not reported.
Limited direct cardiovascular evidence. Antioxidant and anti-inflammatory mechanisms may support vascular health, but no human cardiovascular RCT has tested shilajit as the primary intervention.
AMPK activation has cardioprotective downstream effects, but MOTS-c has no direct cardiovascular RCT. The cardiovascular score stays low because support is indirect, mostly from metabolic pathway reasoning and diabetic animal models rather…
Indirect mitochondrial and anti-inflammatory pathway only. Hodzic Kuerec 2024 found no clear cardiovascular outcome effect across the small human study base.
No human cardiovascular outcome data; composition reviews note antioxidant effects only.
The cardiovascular picture for eloralintide points in two directions at once and no outcome trial exists to settle it. The sponsor reported blood-pressure improvement alongside the weight loss but published no numbers,…
Cardiovascular is the one place GHRP-6 has a distinct research story, but it is preclinical. A second receptor, CD36, mediates a cytoprotective heart effect, per Bodart 2002, and GHRP-6 reduced oxidant damage…
Steffen 2026 (Steffen 2026) found modest observational blood-pressure and hypertension associations in CARDIA and ARIC but no incident cardiovascular-disease association and no Mendelian-randomization support for causality. Sun 2025 supports biomarker-level interest in…
Nothing matches those filters.
Monthly out-of-pocket cost at the most accessible legitimate channel, at the dose the score was given for. 23 of 74 are not priced yet; those cells are left blank rather than guessed.
| Intervention | Monthly cost | At dose | How you get it |
|---|---|---|---|
| Taurine | $3–$10 | 1-3 g, 30-60 minutes before sleep | Over the counter |
| Norwegian 4×4 | Not priced yet | Over the counter | |
| Zone 2 Cardio | Not priced yet | Over the counter | |
| Traditional Sauna (Finnish Dry-Heat) | $50 | 15 to 20 minutes at 80 to 100 C | Over the counter |
| Infrared Sauna | $36–$73 | 55-60 degrees C, 20-30 min | Over the counter |
| HRV Biofeedback | $5 | 20 min/session at individual RF (4.5 to 6.5 bpm) | Over the counter |
| Magnesium | $10–$20 | 200-400 mg glycinate elemental | Over the counter |
| Semaglutide | $199–$349 | 0.25 mg weeks 1 to 4, 0.5 mg weeks 5 to 8, 1.0 mg weeks 9 to 12, 1.7 mg weeks 13 to 16, 2.4 mg week 17 onward | Prescription |
| Polyphenols (Dietary) | Not priced yet | ||
| Spermidine | $40–$90 | 1-3 mg/day oral WGE | Over the counter |
| Tirzepatide | $299–$449 | 2.5 to 5 to 7.5 to 10 to 12.5 to 15 mg | Prescription |
| Spirulina | $10–$25 | 1 to 4.5 g/day | Over the counter |
| Coenzyme Q10 (CoQ10 / Ubiquinol) | $15–$40 | 100-200 mg/day | Over the counter |
| Molecular Hydrogen | Not priced yet | ||
| Metformin | $4–$30 | 500 mg with dinner for 1 week, then 500 mg twice daily for 1 week, then increase by 500 mg/week toward 1000 mg twice daily as tolerated | Prescription |
| Rucking (Weighted Walking) | Not priced yet | ||
| Sprinting (Sprint Interval Training) | Not priced yet | ||
| Berberine | $15–$25 | 500 mg berberine HCl three times daily with meals | Over the counter |
| Blood-Flow Restriction Training | Not priced yet | ||
| Astaxanthin | Not priced yet | ||
| BPC-157 | $40–$80 | 250 to 500 mcg SC 1 to 2x/day near injury site | Grey market |
| TB-500 (Thymosin Beta-4 Fragment) | Not priced yet | ||
| Rapamycin | $15–$50 | 3 mg | Prescription |
| Ergothioneine | Not priced yet | ||
| Chlorella | $10–$50 | 5-10 g/day | Over the counter |
| Senolytics | Not priced yet | ||
| Resveratrol | Not priced yet | ||
| Electrolytes | Not priced yet | ||
| Vitamin D3 + K2 | Not priced yet | ||
| Vitamin C (Ascorbic Acid) | Not priced yet | ||
| Omega-3 | $20–$40 | 1-2 g/day combined EPA+DHA | Over the counter |
| Tesamorelin | $250–$500 | 2 mg subcutaneous daily in the evening | Prescription |
| Exogenous Ketones | $38–$300 | Ester 10 to 25 g BHB | Over the counter |
| Retatrutide | $130–$960 | 2 mg, then 4 mg, then 8 mg or 12 mg weekly depending on protocol and tolerability | Research use only |
| Glycine | $2–$3 | 3 g oral glycine | Over the counter |
| Time-Restricted Eating | Not priced yet | ||
| Quercetin | $20–$50 | 200 mg/day | Over the counter |
| Essential Amino Acids | Not priced yet | ||
| Whole-Body Vibration | $50–$100 | 30 Hz, roughly 0.3g, 10-20 min standing | Over the counter |
| Fucoidan (Brown Seaweed Polysaccharide) | Not priced yet | ||
| SS-31 (Elamipretide) | $200–$500 | 5-10 mg/day subcutaneous | Grey market |
| Quinton Marine Plasma (Seawater Minerals) | Not priced yet | ||
| SLU-PP-332 | $30–$80 | 3-5 mg/day oral | Research use only |
| Ca-AKG (Calcium Alpha-Ketoglutarate) | $15–$30 | 1 g/day generic Ca-AKG oral | Over the counter |
| Earthing | Not priced yet | Over the counter | |
| NR (Nicotinamide Riboside) | $40–$50 | 250-300 mg/day oral | Over the counter |
| Orforglipron (Foundayo) | $149–$299 | Start low, step up to 36 mg | Prescription |
| TRT (Testosterone Replacement Therapy) | $50–$300 | Clinician-selected formulation at the lowest dose likely to restore physiologic testosterone | Prescription |
| Sulforaphane | $25–$60 | Broccoli sprout extract delivering about 150 micromoles sulforaphane per day | Over the counter |
| Hyperbaric Oxygen Therapy | $3,000–$6,000 | 2.0 ATA for 90 minutes with air breaks | In clinic |
| Curcumin | $15–$40 | 500 mg curcuminoids | Over the counter |
| GHK-Cu | $30–$100 | 0.5-3% topical serum or cream | Over the counter |
| Thymosin Beta-4 (Tβ4) | Not priced yet | ||
| GlyNAC (Glycine + N-Acetylcysteine) | $10–$30 | Glycine and NAC at ~100 mg/kg/day each | Over the counter |
| CagriSema (Cagrilintide + Semaglutide) | $80–$160 | 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg of each | Research use only |
| Ozone Therapy | $520–$2,600 | 20-30 mcg/mL ozone, roughly 1,000-1,500 mcg total per session | In clinic |
| L-Theanine | $3–$8 | 200 mg L-theanine + 100 mg caffeine | Over the counter |
| Thymosin Alpha-1 | $100–$400 | 1.6 mg subcutaneous | Prescription |
| Saffron | Not priced yet | ||
| Ketogenic Diet | $100 | Standard keto, 40-50 g total carbohydrate/day | Over the counter |
| NMN (Nicotinamide Mononucleotide) | $40–$100 | 500 mg/day oral | Over the counter |
| Adaptogenic Mushrooms (Reishi, Cordyceps, Chaga) | $15–$40 | 1.5 to 1.8 g/day standardized extract | Over the counter |
| Full-Body EMS | Not priced yet | ||
| Ashwagandha | $15–$30 | 300 mg KSM-66 with breakfast and 300 mg with dinner | Over the counter |
| Tongkat Ali | $20–$40 | 200 mg/day Physta standardized extract | Over the counter |
| Survodutide (BI 456906) | $300–$500 | 2.4, 4.8, or 6.0 mg | Research use only |
| Shilajit | $25–$50 | 500 mg purified shilajit | Over the counter |
| MOTS-c | $100–$200 | 5-10 mg SC | Research use only |
| Urolithin A | $50–$100 | 500 mg/day | Over the counter |
| Glutathione (GSH) | $20–$45 | 1,000 mg/day | Over the counter |
| Pine Pollen | $20–$45 | 5 to 10 g powder per day | Over the counter |
| Eloralintide (LY3841136) | $432–$540 | 9 mg once weekly | Research use only |
| GHRP-6 | $20–$40 | 100 mcg | Grey market |
| C15 (Pentadecanoic Acid) | $40–$50 | 200 mg/day | Over the counter |
Head-to-head reports and category rankings that name a winner on this use case.
This page ranks by the live body-composition subrating, not the overall BioHarmony score, since body composition is the goal this category is built around. Tirzepatide leads both measures.…
This page ranks by the live endurance-cardio subrating, not by BioHarmony overall, and the order flips. SLU-PP-332 leads at 6.5–7.0/10 despite carrying the lowest overall score on the…
BPC-157 wins for acute tendon or muscle injuries, gut healing, and cost-sensitive use. TB-500 wins for cardiac tissue repair and systemic post-surgical recovery. BPC-157 scores 7.5–8.0/10 and TB-500…
No. Berberine scores 6.5–7.0/10 and semaglutide 6.0–6.5/10, and that gap misleads almost everyone who reads it. Berberine scores higher because it is cheap, oral and easy to stop,…
No. Omega-3 scores 6.5–7.0/10 and C15:0 3.0/10, and the evidence behind the two is not close. C15:0 has two small human trials. Omega-3 has outcome trials, prescription forms…
Tesamorelin, unless price is the only thing deciding. It is FDA-approved for visceral fat with Phase 3 trials behind it, while CJC-1295 is a gray-market research peptide whose…
Different jobs, same shelf. Quercetin scores 6.5–7.0/10 and curcumin 5.5–6.0/10, and that gap is the liver-safety signal rather than a difference in effect. Curcumin wins joints, inflammatory markers,…
On weight loss they tie, and neither is a drug you can legitimately buy. Both score 7.5/10 for body composition, and both are investigational Lilly molecules with phase…
No, and the reason is mechanical. A drink raises blood ketones in an hour. It does not lower insulin, deplete glycogen or shift fuel use. The diet scores…
Magnesium glycinate is magnesium bound to glycine, so if you take it you already take both. That kills the question for sleep. The real decision: magnesium scores higher…
Spermidine scores 7.5–8.0/10 and urolithin A 6.5–7.0/10, and they clean up different messes. Spermidine drives broad autophagy: autophagy 8.0/10, cardiovascular 7.8/10, longevity 7.5/10. Urolithin A drives selective mitophagy…
Sulforaphane scores 6.5–7.0/10 and glutathione 6.0–6.5/10, and both have a delivery problem. Sulforaphane needs active myrosinase or you absorb half as much. Plain oral glutathione barely raises blood…
Taurine, at 9.0–9.5 out of 10 for heart health. Guan 2020 reports Confirmed meta-analysis on obesity, BP, and lipid outcomes; supports cardiometabolic breadth.
Of the top-scoring options, Taurine is the least expensive at about $3 a month, scoring 9.0–9.5 out of 10 for heart health.
C15 (Pentadecanoic Acid) scores 3.0–3.5 out of 10 for heart health but only 3.0–3.5 overall, landing in the caution tier once safety, side effects, cost and effort are counted.
74 of the 136 interventions evaluated for heart health score 3.0 out of 10 or better, which is the cut-off for appearing on this page.
